A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma

被引：8

作者：

Diab, Adi

Rahimian, Shah

Haymaker, Cara L.

Bernatchez, Chantale

Andtbacka, Robert Hans Ingemar

James, Marihella

Johnson, Douglas Buckner

Markowitz, Joseph

Murthy, Ravi

Puzanov, Igor

Shaheen, Montaser F.

Swann, Suzanne

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

[2] Idera Pharmaceut Inc, Exton, PA USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX USA

[8] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA

[9] Idera Pharmaceut Inc, Cambridge, MA USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9515

引用

页数：1